sulindac

Summary

Summary: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.

Top Publications

  1. ncbi Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma
    Patricia A Thompson
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724 5024, USA
    Gastroenterology 139:797-805, 805.e1. 2010
  2. ncbi Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice
    Hector Guillen-Ahlers
    W M Keck Center for Transgene Research, University of Notre Dame, Notre Dame, IN 46556, USA
    Carcinogenesis 29:1421-7. 2008
  3. ncbi Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells
    Yuseok Moon
    Department of Microbiology and Immunology and Medical Research Institute, Pusan National University School of Medicine, Busan, 602 739, Republic of Korea
    Toxicol Appl Pharmacol 223:155-63. 2007
  4. ncbi Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation
    Nancy L Cho
    Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Thyroid 20:615-22. 2010
  5. ncbi Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways
    Yuseok Moon
    Department of Microbiology and Immunology and Medical Research Institute, Pusan National University School of Medicine, Busan, 602 739, Republic of Korea
    Life Sci 82:591-9. 2008
  6. ncbi Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta
    A Mi Seo
    Research Center for Women s Diseases, Division of Biological Sciences, Sookmyung Women s University, Seoul 140 742, Korea
    Apoptosis 14:913-22. 2009
  7. ncbi Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
    H M Verheul
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Br J Cancer 79:114-8. 1999
  8. ncbi Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis
    Natalia A Ignatenko
    Department of Cell Biology and Anatomy, Arizona Cancer Center, The University of Arizona, Tucson, USA
    Nutr Cancer 56:172-81. 2006
  9. ncbi Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer
    Tien Hoang
    Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA
    J Thorac Oncol 1:218-25. 2006
  10. ncbi A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    BJU Int 95:963-8. 2005

Research Grants

  1. Combined Chemoprevention in Beta-Catenin Mutant Mice
    Gayle Orner; Fiscal Year: 2004
  2. Using Mouse Endoscopy for Evaluating Colon Cancer
    Daniel Rosenberg; Fiscal Year: 2009
  3. Using Mouse Endoscopy for Evaluating Colon Cancer
    DANIEL WILLIAM ROSENBERG; Fiscal Year: 2010
  4. Combined effects of tea plus NSAIDS towards colon cancer
    Gayle Orner; Fiscal Year: 2004
  5. Dual Modality System for Imaging Colon Cancer in Mice
    Jennifer Kehlet Barton; Fiscal Year: 2010
  6. A novel mouse colon cancer model and chemoprevention
    Wei Dai; Fiscal Year: 2007
  7. Novel mouse colon cancer models and chemoprevention
    Wei Dai; Fiscal Year: 2007
  8. A novel mouse colon cancer model and chemoprevention
    Wei Dai; Fiscal Year: 2010
  9. Novel mouse colon cancer models and chemoprevention
    Wei Dai; Fiscal Year: 2009
  10. CLINICAL PHARMACOLOGY OF NSAIDS IN THE ELDERLY
    D Brater; Fiscal Year: 1992

Detail Information

Publications191 found, 100 shown here

  1. ncbi Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma
    Patricia A Thompson
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724 5024, USA
    Gastroenterology 139:797-805, 805.e1. 2010
    ..We studied effects of the combination of difluoromethylornithine (DFMO) and sulindac on biomarkers and investigated factors that modify their efficacy.
  2. ncbi Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice
    Hector Guillen-Ahlers
    W M Keck Center for Transgene Research, University of Notre Dame, Notre Dame, IN 46556, USA
    Carcinogenesis 29:1421-7. 2008
    ..In this study, Apc(Min/+) mice, a genetic model of human familial adenomatous polyposis, were treated with sulindac, and these mice demonstrated tumor reduction of >80%, consistent with previous reports...
  3. ncbi Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells
    Yuseok Moon
    Department of Microbiology and Immunology and Medical Research Institute, Pusan National University School of Medicine, Busan, 602 739, Republic of Korea
    Toxicol Appl Pharmacol 223:155-63. 2007
    ..In the present study, NSAID sulindac sulfide was investigated for the cytotoxic injury in the intestinal epithelial cells in association with an ..
  4. ncbi Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation
    Nancy L Cho
    Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Thyroid 20:615-22. 2010
    ..In this study, we tested the hypothesis that the nonsteroidal antiinflammatory drug sulindac would reverse aberrant beta-catenin activity in thyroid cancer cells.
  5. ncbi Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways
    Yuseok Moon
    Department of Microbiology and Immunology and Medical Research Institute, Pusan National University School of Medicine, Busan, 602 739, Republic of Korea
    Life Sci 82:591-9. 2008
    ..Among diverse NSAIDs, sulindac sulfide was most potent of inducing the human TSP-1 protein expression...
  6. ncbi Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta
    A Mi Seo
    Research Center for Women s Diseases, Division of Biological Sciences, Sookmyung Women s University, Seoul 140 742, Korea
    Apoptosis 14:913-22. 2009
    b>Sulindac is a non-steroidal anti-inflammatory agent with anti-tumor activities that include the induction of apoptosis in various cancer cells and the inhibition malignant transformation...
  7. ncbi Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
    H M Verheul
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Br J Cancer 79:114-8. 1999
    ..We found that sulindac was one of the most potent antiangiogenic NSAIDs, inhibiting bFGF-induced neovascularization by 50% and VEGF-..
  8. ncbi Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis
    Natalia A Ignatenko
    Department of Cell Biology and Anatomy, Arizona Cancer Center, The University of Arizona, Tucson, USA
    Nutr Cancer 56:172-81. 2006
    The nonsteroidal antiinflammatory drug sulindac displays chemopreventive activity in patients with familial adenomatous polyposis (FAP)...
  9. ncbi Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer
    Tien Hoang
    Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA
    J Thorac Oncol 1:218-25. 2006
    ..1 months in phase II), we did not observe a clear survival advantage and thus do not plan to further investigate this schedule of gemcitabine and exisulind...
  10. ncbi A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    BJU Int 95:963-8. 2005
    To determine the safety and efficacy, in a dose-escalation study, of exisulind (an oral sulphone metabolite of sulindac thought to induce apoptosis in malignant cells by inhibiting cGMP-phosphodiesterase) combined with docetaxel in men ..
  11. ncbi Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma
    Victoria J Sinibaldi
    Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Am J Clin Oncol 29:395-8. 2006
    ....
  12. ncbi Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells
    Pamela L Rice
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Mol Cancer Ther 2:885-92. 2003
    ..Substantial clinical, epidemiological, and animal evidence indicate that sulindac and other non-steroidal anti-inflammatory drugs (NSAIDs) prevent the development of CRC...
  13. ncbi A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer
    Suzanne F Jones
    The Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Lung Cancer 6:361-6. 2005
    Exisulind is a sulfone derivative of sulindac that induces apoptosis and demonstrates synergy with docetaxel in lung cancer models...
  14. ncbi Sulindac suppresses tumorigenesis in the Min mouse
    Y Beazer-Barclay
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Carcinogenesis 17:1757-60. 1996
    ..of this model for the evaluation and optimization of chemopreventive agents, we examined the effects of sulindac on tumorigenesis in Min mice as this compound can inhibit colorectal tumorigenesis in human familial adenomatous ..
  15. ncbi Sulindac sulfide induces autophagic death in gastric epithelial cells via survivin down-regulation: a mechanism of NSAIDs-induced gastric injury
    Shiun Kwei Chiou
    Department of Veterans Affairs Medical Center, Long Beach, CA 90822 5201, USA
    Biochem Pharmacol 81:1317-23. 2011
    b>Sulindac sulfide, a nonsteroidal anti-inflammatory drug (NSAID), has anti-tumorigenic and anti-inflammatory activities, but causes gastric mucosal damage...
  16. ncbi Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis
    J J Keller
    Department of Pathology, Academic Medical Center, 1100 DD Amsterdam, The Netherlands
    Clin Cancer Res 7:4000-7. 2001
    b>Sulindac causes the reduction of adenomas in familial adenomatous polyposis (FAP) patients, but complete regression is unusual, and breakthrough of colorectal carcinoma during sulindac treatment has been described...
  17. ncbi A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501)
    Gregory A Masters
    Christiana Care CCOP, Newark, Delaware, USA
    J Thorac Oncol 1:673-8. 2006
    ..The statistical endpoint of 17 patients alive at 18 months was met, but given ongoing developments in advanced NSCLC, ECOG will not be pursuing additional trials of exisulind in NSCLC...
  18. ncbi Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer?
    F Tonelli
    Department of Clinical Physiopathology, Surgical Unit, University of Florence, Italy
    J Surg Oncol 74:15-20. 2000
    Ileorectal anastomosis (IRA) is still used in the treatment of familial adenomatous polyposis (FAP). Sulindac appears to induce regression of colorectal adenomas; however, its effects in long-term therapy and in preventing carcinoma ..
  19. ncbi Effects of long-term administration of sulindac on APC mRNA and apoptosis in colons of rats treated with azoxymethane
    Y Kishimoto
    Division of Pharmacotherapeutics, Department of Pathophysiological and Therapeutic Science, Faculty of Medicine, Tottori University, 86 Nishicho, Yonago 683 8503, Japan
    J Cancer Res Clin Oncol 128:589-95. 2002
    Non-steroidal anti-inflammatory drugs, including sulindac, have been shown to exhibit anti-colon cancer activity; however, the detailed mechanisms concerning continuous long-term administration are still unclear...
  20. ncbi The influence of sulindac on experimental streptozotocin-induced diabetic neuropathy
    D W Zochodne
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Can J Neurol Sci 21:194-202. 1994
    We studied the influence of sulindac, a nonsteroidal anti-inflammatory agent on experimental streptozotocin-induced diabetic neuropathy...
  21. ncbi Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice
    Gerardo G MacKenzie
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, New York 11794 8173, USA
    Gastroenterology 139:1320-32. 2010
    ..However, chronic administration of NSAIDs is associated with significant side effects, mainly of the gastrointestinal tract. Given these limitations, we synthesized phospho-sulindac (P-S; OXT-328), a novel sulindac derivative.
  22. ncbi Mechanisms of sulindac-induced apoptosis and cell cycle arrest
    Barbara Jung
    Department of Molecular Biology, Sidney Kimmel Cancer Center, 10835 Altman Row, San Diego, CA 92121, USA
    Cancer Lett 219:15-25. 2005
    The mechanism underlying the chemopreventive effects of the non-steroidal anti-inflammatory drug sulindac remains unclear. Its active metabolite, sulindac sulfide, induces cell cycle arrest as well as apoptosis in mammalian cell lines...
  23. ncbi Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases
    Jung Hyun Park
    Department of Internal Medicine, Institute of Wonkwang Medical Science, Wonkwang University, School of Medicine, Jeonbuk 570 749, South Korea
    Oncol Rep 20:379-84. 2008
    ..b>Sulindac is known to enhance the cellular responsiveness of tumors toward chemotherapeutic drugs...
  24. ncbi Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations
    Svenja D Steinbrink
    Institute of Pharmaceutical Chemistry ZAFES, Goethe University, Max von Laue Str 9, 60438, Frankfurt Main, Germany
    Cell Mol Life Sci 67:797-806. 2010
    b>Sulindac is a non-selective inhibitor of cyclooxygenases (COX) used to treat inflammation and pain...
  25. ncbi Autophagy delays sulindac sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29
    C Bauvy
    INSERM U504 Glycobiologie et Signalisation Cellulaire, 16, avenue Paul-Vaillant Couturier, 94807 Villejuif Cedex, France
    Exp Cell Res 268:139-49. 2001
    ..that 3-methyladenine, an inhibitor of autophagy, increases the sensitivity of HT-29 cells to apoptosis induced by sulindac sulfide, a nonsteroidal anti-inflammatory drug which inhibits the cyclooxygenases...
  26. ncbi Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors
    W R Waddell
    Department of Surgery, University of Arizona, Tucson
    Am J Surg 161:416-21. 1991
    ..e., more than 50% reduction in volume. Eight patients received nonsteroid anti-inflammatory drugs (indomethacin, sulindac, or sulindac with warfarin and vitamin K1 [Mephyton]) for periods of 2 to 91 months...
  27. ncbi Sulindac to prevent recurrent preterm labor: a randomized controlled trial
    R G Humphrey
    Department of Obstetrics and Gynecology, Arnold Palmer Hospital for Children and Women, Orlando, Florida, USA
    Obstet Gynecol 98:555-62. 2001
    OBJECTIVE: To assess the efficacy of oral sulindac in low doses for prolonged duration to decrease the risk of recurrent preterm labor and extend gestation...
  28. ncbi Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system
    Frantzy Etienne
    Center for Molecular Biology and Biotechnology, Florida Atlantic University, Boca Raton, FL, USA
    Biochem Biophys Res Commun 312:1005-10. 2003
    b>Sulindac is a known anti-inflammatory drug that functions by inhibition of cyclooxygenases 1 and 2 (COX)...
  29. ncbi Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice
    Ying Hu
    Department of Medicine Flinders University of South Australia, Adelaide, Australia
    Int J Cancer 116:870-5. 2005
    ..We tested the ability of sulindac to reverse these defects...
  30. ncbi The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells
    Nikolaos G Nikitakis
    Department of Diagnostic Sciences and Pathology, University of Maryland, Baltimore, Maryland 21201-1586, USA
    Cancer Res 62:1004-7. 2002
    The nonsteroidal anti-inflammatory drug sulindac exerts a significant antineoplastic effect on several types of human cancers including oral squamous cell carcinoma (SCCa)...
  31. ncbi Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
    S K Boolbol
    Strang Cancer Prevention Center, New York, 10021, USA
    Cancer Res 56:2556-60. 1996
    ..apoptosis in cultured epithelia] cells, an activity that is reversed by the nonsteroidal anti-inflammatory drug, sulindac sulfide...
  32. ncbi Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction
    Sung Keum Seo
    Laboratory of Functional Genomics, Korea Institute of Radiological and Medical Sciences, 215 4 Gongneung dong, Nowon Ku, Seoul, 139 706, Republic of Korea
    Apoptosis 12:195-209. 2007
    ..The purpose of this study was to elucidate the potential signaling components underlying sulindac-induced apoptosis in human multiple myeloma (MM) cells...
  33. ncbi Primary chemoprevention of familial adenomatous polyposis with sulindac
    Francis M Giardiello
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
    N Engl J Med 346:1054-9. 2002
    ..The subjects received either 75 or 150 mg of sulindac orally twice a day or identical-appearing placebo tablets for 48 months...
  34. ncbi Non-steroidal anti-inflammatory agents, tolmetin and sulindac, inhibit liver tryptophan 2,3-dioxygenase activity and alter brain neurotransmitter levels
    A Dairam
    Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa
    Life Sci 79:2269-74. 2006
    ..In this study, we determined the effect of the non-steroidal anti-inflammatory agents, tolmetin and sulindac, on rat liver TDO activity and the subsequent changes in the hippocampal and striatal neurotransmitter levels...
  35. ncbi Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model
    Xiaoxin Chen
    Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, State University of New Jersey, 164 Frelinghuysen Road, Piscataway 08854, USA
    Carcinogenesis 23:2095-102. 2002
    ..b>Sulindac (a Cox inhibitor), nordihydroguaiaretic acid (NDGA, a lipoxygenase inhibitor) and alpha-difluoromethylornithine (..
  36. ncbi Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity
    Takae Minami
    First Department of Internal Medicine, Graduate School of Medicine, Sapporo Medical University, Sapporo, Japan
    Clin Cancer Res 11:5248-56. 2005
    PURPOSE: The nonsteroidal antiinflammatory drug sulindac is a promising chemopreventive agent against colon cancer...
  37. ncbi Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis
    Russell F Jacoby
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA
    Gastroenterology 127:838-44. 2004
    ..epidemiological data, and clinical trials in patients with adenomatous polyposis have consistently indicated that sulindac and other nonsteroidal antiinflammatory drugs or cyclooxygenase inhibitors have the greatest potential efficacy ..
  38. ncbi Combination of tumor necrosis factor-alpha with sulindac in human carcinoma cells in vivo
    Hiroshi Yasui
    First Department of Internal Medicine, Sapporo Medical University School of Medicine, S 1, W 16, Chuo Ku, Sapporo, 060 8543, Japan
    Ann N Y Acad Sci 1010:273-7. 2003
    ..Recently, the nonsteroidal anti-inflammatory drug (NSAID) sulindac and its metabolites have been shown to inhibit the NF-kappaB-mediated survival signals through inhibition of IKK-..
  39. ncbi Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane
    Tomokazu Ohishi
    School of Food and Nutritional Sciences, University of Shizuoka, 52-1 Yada, Shizuoka 422-8526, Japan
    Cancer Lett 177:49-56. 2002
    ..b>Sulindac is also well known as a cancer-preventive agent against colon cancer, but its usage is restricted because of its ..
  40. ncbi Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)
    Dae J Kim
    Department of Veterinary and Biomedical Sciences and The Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA, 16802, USA
    Carcinogenesis 27:1105-12. 2006
    ..32 g sulindac/kg diet...
  41. ncbi Sulindac suppresses beta-catenin expression in human cancer cells
    Anjia Han
    Department of Pathology, University of Illinois at Chicago, Chicago, IL 60612, USA
    Eur J Pharmacol 583:26-31. 2008
    b>Sulindac has been reported to be effective in suppressing tumor growth through the induction of p21WAF1/cip1 in human, animal models of colon cancer and colon cancer cells...
  42. ncbi Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer
    Naveen Babbar
    Arizona Cancer Center, and Biochemistry, Molecular and Cellular Biology Graduate Program, The University of Arizona, Tucson, 85724, USA
    J Biol Chem 278:47762-75. 2003
    b>Sulindac, a non-steroidal anti-inflammatory prodrug, is metabolized into pharmacologically active sulfide and sulfone derivatives...
  43. ncbi Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis
    F M Giardiello
    Department of Medicine, Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Dig Dis Sci 43:311-6. 1998
    ..specimens of flat rectal mucosa from four patients with familial adenomatous polyposis (FAP) before and after sulindac therapy and from five healthy individuals...
  44. ncbi Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro
    T T Jiang
    Dept of Radiation Oncology, Henry Ford Health Sciences Center, Detroit, Michigan 48098, USA
    J Exp Clin Cancer Res 23:259-62. 2004
    ..In this study we tested sulindac sulfide, a nonsteroidal anti-inflammatory drug (NSAID) to test its effects with arsenic...
  45. ncbi Defective acute apoptotic response to genotoxic carcinogen in small intestine of APC(Min/+) mice is restored by sulindac
    Ying Hu
    Department of Medicine, Flinders University of South Australia, Adelaide, Australia
    Cancer Lett 248:234-44. 2007
    ..effect of APC loss on azoxymethane (AOM)-induced apoptosis and cell proliferation, as well as their regulation by sulindac was examined in colon and small intestine in APC(Min/+) mice...
  46. ncbi Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-kappaB in HCT116 colon cancer cells
    Hye Ran Lee
    Department of Internal Medicine, Inje University, Ilsan Paik Hospital, Seoul 140 743, Korea
    Oncol Rep 20:41-7. 2008
    ..the apoptotic effect of arsenic trioxide (As2O3) on colon cancer cells could be enhanced by the addition of sulindac, HCT116 cells were treated with As2O3 (1, 5, 10 microM) and sulindac (0.5 mM), either alone or in combination...
  47. ncbi Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac
    N N Mahmoud
    The New York Hospital Cornell Medical Center, New York 10021, USA
    Cancer Res 59:353-9. 1999
    ..This effect was reversed upon treatment of Min/+ mice with the chemopreventive drug sulindac sulfide...
  48. ncbi Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line
    Morag C Jarvis
    Biomedical Research Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK
    Oncogene 24:8211-5. 2005
    Nonsteroidal anti-inflammatory drugs (NSAIDs) including sulindac sulfide are known to exert cancer chemopreventative activity in a range of cell lines...
  49. ncbi Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Mol Cancer Ther 6:1736-44. 2007
    ..with NF-kappaB inhibition, enhanced the growth suppression of pancreatic cancer cells by the COX inhibitor sulindac in vitro...
  50. ncbi Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells
    Yunjie Sun
    Division of Gastroenterology Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Mol Cancer Ther 4:51-9. 2005
    The nonsteroidal anti-inflammatory drug (NSAID) sulindac prevents experimental colon cancer and can regress precancerous polyps in humans...
  51. ncbi Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells
    M Adachi
    First Department of Internal Medicine, Graduate School of Medicine, Sapporo Medical University, Sapporo, Japan
    Histol Histopathol 22:437-42. 2007
    ..In addition, the classical NSAIDs sulindac and aspirin are promising chemopreventive agents against colon cancer...
  52. ncbi Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L)
    Rajani Ravi
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Cancer Res 62:1583-7. 2002
    ..either a peptide that disrupts the inhibitor of kappaB kinase complex or the nonsteroidal anti-inflammatory drug, sulindac sulfide...
  53. ncbi Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis
    Tae Jung Jang
    Department of Pathology, Dongguk University College of Medicine, Suek jang Dong 707, Kyongju, Kyongbuk 780 714, Korea
    Carcinogenesis 25:1853-8. 2004
    ..We found that NAG-1 expression was strongly induced in SNU601 cells, which lack endogenous COX-2, by sulindac sulfide, and that this was closely related with increased apoptosis and decreased cell viability...
  54. ncbi p21(WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo
    W Yang
    Department of Oncology, Albert Einstein Cancer Center, Bronx, New York 10467, USA
    Cancer Res 61:6297-302. 2001
    b>Sulindac, a nonsteroidal anti-inflammatory drug, inhibits intestinal tumorigenesis in humans and rodents. Sulindac induced complex alterations in gene expression, but only 0...
  55. ncbi Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas
    Jason A Zell
    Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA
    Cancer Prev Res (Phila) 2:209-12. 2009
    ..of baseline CV risk on adverse CV events in a phase III trial of difluoromethylornithine (DFMO) plus the NSAID sulindac versus placebo in preventing colorectal adenomas. Trial data were analyzed to determine baseline CV risk...
  56. ncbi Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats
    Michael H Mesches
    Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA
    Neurobiol Aging 25:315-24. 2004
    ..b>Sulindac, an NSAID that is a nonselective cyclooxygenase (COX) inhibitor was chronically administered to aged Fischer 344 ..
  57. ncbi Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)
    Gayle A Orner
    Department of Environmental and Molecular Toxicology, 571 Weniger Hall, Linus Pauling Institute, Oregon State University, Corvallis, OR 97331-6512, USA
    Mutat Res 506:121-7. 2002
    ..Res. 495 (2001) 61]. We compared the inhibitory effects of white and green teas with sulindac, a nonsteroidal anti-inflammatory agent, in two different mouse models of intestinal tumorigenesis...
  58. ncbi Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis
    I Guldenschuh
    Gastroenterology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
    Dis Colon Rectum 44:1090-7; discussion 1097-9. 2001
    ..The nonsteroidal anti-inflammatory agent sulindac has been shown to reduce the number of colorectal adenomas...
  59. ncbi Dietary anthocyanin-rich tart cherry extract inhibits intestinal tumorigenesis in APC(Min) mice fed suboptimal levels of sulindac
    Gerd Bobe
    Department of Food Science and Human Nutrition, Bioactive Natural Products and Phytoceuticals, Department of Horticulture, and National Food Safety and Toxicology Center, Michigan State University, East Lansing, MI 44824, USA
    J Agric Food Chem 54:9322-8. 2006
    ..tart cherry extract were fed in combination with suboptimal levels of the nonsteroidal anti-inflammatory drug sulindac to APCMin mice for 19 weeks...
  60. ncbi High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors
    N Julian H Sturt
    Cancer 101:652; author reply 653. 2004
  61. ncbi Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy
    K J Smith
    Department of Dermatology and Pathology, National Naval Medical Center, Bethesda, Maryland 20889 5600, USA
    Dermatol Surg 27:143-6. 2001
    ..Patients with chronic lymphocytic leukemia (CLL) often have a protracted course. However, all these patients are immunosuppressed and may have a high incidence of cutaneous malignancies...
  62. ncbi Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-dependent biology
    Andrew S Felts
    ACS Chem Biol 2:479-83. 2007
    ..Potent COX inhibitors exist, but they display off-target effects. 2'-Desmethyl derivatives of indomethacin and sulindac sulfide were synthesized that demonstrated reduced COX inhibitory activity but were inducers of peroxisome ..
  63. ncbi Chemoprevention with special reference to inherited colorectal cancer
    Patrick M Lynch
    Department of Gastrointestinal Medicine and Nutrition 436, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 1402, USA
    Fam Cancer 7:59-64. 2008
    ..era was ushered in by the recognition that antiarthritic doses of a nonsteroidal anti-inflammatory agent (NSAID), sulindac, could actually induce regression of colorectal adenomas in patients with FAP...
  64. ncbi Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice
    M F McEntee
    Department of Pathology and Nutrition, University of Tennessee, Knoxville 37901, USA
    Carcinogenesis 20:635-40. 1999
    ..We recently showed that sulindac causes regression of 70-80% of small intestinal tumors in Min/+ mice within 4 days, but does not have the same ..
  65. ncbi PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
    T C He
    Johns Hopkins Oncology Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cell 99:335-45. 1999
    ..Reporters containing PPARdelta-responsive elements were repressed by the NSAID sulindac. Furthermore, sulindac was able to disrupt the ability of PPARdelta to bind its recognition sequences...
  66. ncbi Modulation by colony stimulating factors of human epithelial colon cancer cell apoptosis
    Sara Calatayud
    Unit of Critical Care, The Royal Brompton and Harefield N H S Trust, Imperial College School of Medicine, Sydney Street, London, SW 6NP, UK
    Cytokine 20:163-7. 2002
    ..Moreover, reduced apoptosis induced by sulindac sulfide was also observed with macrophage-CSF...
  67. ncbi Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention
    J L Williams
    American Health Foundation, One Dana Road, Valhalla, NY 06595
    Cancer Res 61:3285-9. 2001
    ..To assess their potential in colon cancer chemoprevention, we studied in vitro the effect of NO-aspirin, NO-sulindac, and NO-ibuprofen on colonocyte kinetics...
  68. ncbi Resistance to apoptosis is increased during metastatic dissemination of colon cancer
    L Oliver
    INSERM U 419, IFR 26, Nantes, France
    Clin Exp Metastasis 19:175-80. 2002
    ..this question, we have analyzed the sensitivity to cell death induced by non-steroid anti-inflammatory drug, Sulindac, the most common drug used in colon cancer chemotherapy, 5-fluorouracil (5-FU) and the short chain fatty acid, ..
  69. ncbi Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells
    H Weiss
    Department of General Surgery, University Hospital Innsbruck and The Tyrolean Cancer Research Institute, Innsbruck, Austria
    Int J Cancer 92:877-82. 2001
    ..Acetyl-salicylic-acid (ASA), mefenamic acid (MEF) and sulindac sulfide (SUS) inhibited cell proliferation with the following order of potency: SUS > MEF >> ASA...
  70. ncbi The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3)
    Frank G Bottone
    Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, P.O. Box 12233, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA
    Mol Cancer Ther 4:693-703. 2005
    We previously showed that nonsteroidal anti-inflammatory drugs (NSAID) such as sulindac sulfide, which has chemopreventive activity, modulate the expression of several genes detected by microarray analysis...
  71. ncbi Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition
    Jonathan M Bock
    Department of Otolaryngology Head and Neck Surgery, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA
    Mol Carcinog 46:857-64. 2007
    ..MTT assay was used to calculate IC(50) values in UM-SCC-1 cells for 10 NSAIDs, including celecoxib, rofecoxib, sulindac sulfide, sulindac sulfone, indomethacin, ketoprofen, flurbiprofen, naproxen, piroxicam, and aspirin...
  72. ncbi Uncoupling of oxidative phosphorylation and Smac/DIABLO release are not sufficient to account for induction of apoptosis by sulindac sulfide in human colorectal cancer cells
    Mikael Daouphars
    Laboratoire de Physiopathologie et Pharmacologie Articulaires, UMR 7561 CNRS-UHP, , , , France
    Int J Oncol 26:1069-77. 2005
    ..To assess the possible contribution of uncoupling to their antineoplastic properties, we compared the effect of sulindac sulfide (SS), an acidic NSAID and NS-398, a non-acidic tricyclic, on mitochondrial function and apoptosis in ..
  73. ncbi 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line
    Virginie Quidville
    Institut National de la Santé et de la Recherche Médicale U 606, Paris 75010, France
    Prostaglandins Other Lipid Mediat 81:14-30. 2006
    ..Here, we show that the COX-1 inhibitors, selective or not, and sulindac sulfone, a non-COX inhibitor, increased 15-PGDH activity and reduced PGE2 levels...
  74. ncbi Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest
    Katharina M Detjen
    Medizinische Klinik mit Schwerpunkt Hepatologie, Gastroenterologie, Endokrinologie und Stoffwechsel, , Campus Virchow Klinikum, , Berlin, Germany
    Int J Cancer 107:844-53. 2003
    ..Growth-inhibitory effects were achieved with either COX-2 selective (NS398) or unselective (indomethacin, sulindac) compounds. Cell-cycle analyses documented a G1 arrest in NSAID-treated GEP NET populations...
  75. ncbi [The growth inhibition of colorectal adenoma cells by sulindac and its mechanisms]
    Libin Huang
    Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China
    Hua Xi Yi Ke Da Xue Xue Bao 33:101-3. 2002
    OBJECTIVE: This study was conducted to assess the growth inhibition of colorectal adenoma cells by sulindac and identify the possible mechanisms...
  76. ncbi Lactacystin augments the sulindac-induced apoptosis in HT-29 cells
    H J Choi
    Department of General Surgery, Dong-A University College of Medicine, Dongdaesin-Dong, Seo Gu, Pusan 602-714, South Korea
    Apoptosis 8:301-5. 2003
    ..We employed sulindac as a NSAID, and chose the lactacystin for inhibition of proteasome activity...
  77. ncbi Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines
    Adel Kardosh
    Department of Molecular Microbiology and Immunology, University of Southern California, Los Angeles, California, USA
    Cancer Biol Ther 3:55-62. 2004
    ....
  78. ncbi Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells
    B Agarwal
    Division of Gastroenterology, St Louis University, School of Medicine, St Louis, MO 63105, USA
    Apoptosis 8:649-54. 2003
    ..In contrast, sulindac sulfide (SSD) (which inhibits Cox-1 and Cox-2) 0-200 microM or sulindac sulfone (SSN) 0-500 microM (without ..
  79. ncbi Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1
    Yuseok Moon
    Eicosanoid Biochemistry Section, Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, USA
    Mol Cancer Ther 4:1551-8. 2005
    ..the gene regulatory and anti-invasive activity of two traditional nonsteroidal anti-inflammatory drugs (NSAID), sulindac sulfide and indomethacin...
  80. ncbi Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?
    Ian Chau
    N Engl J Med 346:1085-7. 2002
  81. ncbi Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells
    B H Park
    Johns Hopkins Oncology Center and Howard Hughes Medical Institute, 1650 Orleans Street, Room 590, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 98:2598-603. 2001
    ..These data suggest that suppression of PPARdelta expression contributes to the growth-inhibitory effects of the APC tumor suppressor...
  82. ncbi GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells
    Imad Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 62:1178-83. 2002
    ..Ectopic GATA-6 expression blocked NSAID induction of 15-LOX-1 and apoptosis. NSAIDs down-regulate GATA-6 to transcriptionally up-regulate 15-LOX-1 and induce apoptosis in colorectal cancer cells...
  83. ncbi Polyamines reverse non-steroidal anti-inflammatory drug-induced toxicity in human colorectal cancer cells
    Alun Hughes
    Department of Medicine, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK
    Biochem J 374:481-8. 2003
    Naproxen, sulindac and salicylate, three NSAIDs (non-steroidal anti-inflammatory drugs), were cytotoxic to human colorectal cancer cells in culture. Toxicity was accompanied by significant depletion of intracellular polyamine content...
  84. ncbi Comparison of the anti-proliferation and apoptosis-induction activities of sulindac, celecoxib, curcumin, and nifedipine in mismatch repair-deficient cell lines
    Shu-Chen Wei
    Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
    J Formos Med Assoc 103:599-606. 2004
    ..This study compared the anticancer effects of sulindac, celecoxib, curcumin, and nifedipine in MMR-deficient cell lines, in order to determine the most appropriate ..
  85. ncbi Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen
    W J Wechter
    Loma Linda University Medical Center, Department of Medicine, California 92350, USA
    Life Sci 66:745-53. 2000
    ..o.d.) schedule and compares it with sulindac sulfone. The q.o.d. schedule at 10 mg/kg was equally efficacious as qd treatment at the same dose. For the q.o.d...
  86. ncbi Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation
    Han Li
    Cell Pathways, Inc, 702 Electronic Drive, Horsham, PA 19044, USA
    Biochem Pharmacol 64:1325-36. 2002
    ....
  87. ncbi Induction of apoptosis by sulindac sulfide in HL60 cells is enhanced by p21CiP1 or p27KiP1
    A E Ikui
    Department of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Anticancer Res 21:2297-303. 2001
    The nonsteroidal anti-inflammatory drug (NSAID) sulindac and its derivatives induce apoptosis in a variety of carcinoma cells in vitro and display antitumor effects in vivo...
  88. ncbi New indene-derivatives with anti-proliferative properties
    Ioanna-Maria Karaguni
    Max-Planck-Institut fur Molekulare Physiologie, Dortmund, Germany
    Bioorg Med Chem Lett 12:709-13. 2002
    Metabolites of the non-steroidal anti-inflammatory drug Sulindac inhibit cell proliferation by affecting several intracellular signaling pathways including the tumorigenic Ras/Raf/MAPK pathway...
  89. ncbi A Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line
    Z Han
    Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island 02912, USA
    J Biol Chem 276:38748-54. 2001
    ..The NSAIDs indomethacin and sulindac sulfide have been shown to induce apoptosis of colon epithelial cancer cells by a Bax-dependent mechanism that ..
  90. ncbi Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines
    Susumu Hashitani
    Department of Oral and Maxillofacial Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan
    Int J Oncol 23:665-72. 2003
    ..head and neck carcinoma cell lines, SCC25, KB, HSG and HSY, in comparison with frequently used COX inhibitor sulindac. Also, we examined whether celecoxib augments the sensitivity of these cell lines to anticancer drugs such as ..
  91. ncbi [Chemoprevention of colorectal cancer]
    R Benamouzig
    , , 125, rue de Stalingrad, F93000 Bobigny
    Presse Med 31:124-7. 2002
    ..THE PRINCIPLE AGENTS UNDER ASSESSMENT: Are aspirin, type 2 cyclo-oxygenase inhibitors, calcium, folic acid, certain vitamins, hormone replacement therapy for menopausal women and difluoromethylornithine (DFMO)...
  92. ncbi Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer
    M A Scheper
    Department of Diagnostic Sciences and Pathology, Dental School, University of Maryland, Baltimore, 650 W Baltimore Ave 7 North, Baltimore, MD 21201, USA
    Int J Oral Maxillofac Surg 36:632-9. 2007
    b>Sulindac exerts its antitumorigenic effects in oral squamous cell carcinoma (SCC) cells by modulating survivin in a Stat3-dependent manner...
  93. ncbi Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon
    Jun Yang Liou
    University of Texas Health Science Center, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 67:3185-91. 2007
    ..colorectal cancer apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs), we evaluated the effects of sulindac on 14-3-3epsilon protein expression in colorectal cancer cells...
  94. ncbi Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients
    Jan J Koornstra
    Department of Gastroenterology and Hepatology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
    Cancer Epidemiol Biomarkers Prev 14:1608-12. 2005
    b>Sulindac reduces colorectal cancer risk in genetically susceptible humans and animals. The molecular mechanisms underlying these effects are incompletely understood...
  95. ncbi Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells
    Qin He
    Department of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York, NY 13210, USA
    Oncogene 21:6032-40. 2002
    ..Here we report that two different NSAIDs, sulindac sulfide and SC-'236 engage the death receptor 5 (DR5) and mitochondrial pathways to mediate apoptosis in human ..
  96. ncbi Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells
    Y Huang
    Department of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York 13210, USA
    Cancer Res 61:6918-24. 2001
    b>Sulindac is the most extensively investigated clinically relevant chemopreventive nonsteroidal anti-inflammatory drug...
  97. ncbi Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites
    P L Rice
    Department of Medicine, University of Colorado Health Science Center, Denver 80262, USA
    Cancer Res 61:1541-7. 2001
    Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and sulindac is associated with a decreased mortality from colorectal cancer...
  98. ncbi Proapoptotic anti-inflammatory drugs
    C Myers
    University of Virginia Medical School, Charlottesville, Virginia 22908, USA
    Urology 57:73-6. 2001
    ..including selective cyclooxygenase-2 inhibitors, lipoxygenase inhibitors, and novel NSAID derivatives (eg, sulindac sulfone and R-flurbiprofen), offer the promise of oral, nontoxic agents able to control the progression of ..
  99. ncbi PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells
    Nikolaos G Nikitakis
    Department of Diagnostic Sciences and Pathology, University of Maryland, Baltimore, MD 21201 1586, USA
    Int J Cancer 98:817-23. 2002
    There is strong evidence that nonsteroidal antiinflammatory drug (NSAID) sulindac may exert a significant antineoplastic effect...
  100. ncbi COX-2 inhibition and colorectal cancer
    Claus-Henning Koehne
    Berelchsleiter Internistische Onkologie, Medizinische Klinik und Poliklinik I, Universitatsklinik Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany
    Semin Oncol 31:12-21. 2004
    ..The role of celecoxib in cancer treatment is still evolving. Recent studies have identified a potential benefit for adding celecoxib to standard CRC chemotherapy regimens to increase their efficacy and reduce their associated toxicity...
  101. ncbi [Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas]
    Hans H Raskov
    Amtssygehuset i Gentofte, Kirurgisk afdeling D, Hellerup
    Ugeskr Laeger 168:359-62. 2006

Research Grants73

  1. Combined Chemoprevention in Beta-Catenin Mutant Mice
    Gayle Orner; Fiscal Year: 2004
    ..A combination of tea plus the NSAID sulindac was recently shown to be highly effective at preventing the formation of tumors in Apc[min] mice...
  2. Using Mouse Endoscopy for Evaluating Colon Cancer
    Daniel Rosenberg; Fiscal Year: 2009
    ..We will use sulindac, currently being tested in an NCI multi-center pilot chemoprevention clinical trial (CPN), as a model ..
  3. Using Mouse Endoscopy for Evaluating Colon Cancer
    DANIEL WILLIAM ROSENBERG; Fiscal Year: 2010
    ..We will use sulindac, currently being tested in an NCI multi-center pilot chemoprevention clinical trial (CPN), as a model ..
  4. Combined effects of tea plus NSAIDS towards colon cancer
    Gayle Orner; Fiscal Year: 2004
    ..Our preliminary data shows that tea or a combination of tea plus the NSAID sulindac is highly effective at preventing the formation of tumors in Apc m/In mice...
  5. Dual Modality System for Imaging Colon Cancer in Mice
    Jennifer Kehlet Barton; Fiscal Year: 2010
    ..progress to adenoma and/or adenocarcinoma? b) Can treatment with 1-difluoromethylornithine (DFMO) and/or sulindac regress adenoma and prevent adenocarcinoma? c) What role does the RAS oncogene play in sulindac prevention of ..
  6. A novel mouse colon cancer model and chemoprevention
    Wei Dai; Fiscal Year: 2007
    ..Moreover, chemopreventive compounds such as sulindac sulfide and S-allylmercaptocysteine are capable of inducing apoptosis in HT-29 and SW-480 colon tumor cells; ..
  7. Novel mouse colon cancer models and chemoprevention
    Wei Dai; Fiscal Year: 2007
    ..Moreover, chemopreventive compounds such as sulindac sulfide and S-allylmercaptocysteine are capable of inducing apoptosis in HT-29 and SW-480 colon tumor cells; ..
  8. A novel mouse colon cancer model and chemoprevention
    Wei Dai; Fiscal Year: 2010
    ..Moreover, chemopreventive compounds such as sulindac sulfide and S-allylmercaptocysteine are capable of inducing apoptosis in HT-29 and SW-480 colon tumor cells;BubRl ..
  9. Novel mouse colon cancer models and chemoprevention
    Wei Dai; Fiscal Year: 2009
    ..Moreover, chemopreventive compounds such as sulindac sulfide and S-allylmercaptocysteine are capable of inducing apoptosis in HT-29 and SW-480 colon tumor cells; ..
  10. CLINICAL PHARMACOLOGY OF NSAIDS IN THE ELDERLY
    D Brater; Fiscal Year: 1992
    ..In the former, we will use balance and clearance techniques to examine the effects of ibuprofen, sulindac and piroxicam on renal function...
  11. Chemoprevention of Tobacco Related Cancer in Animals
    Michael Pereira; Fiscal Year: 2004
    ..budesonide and the farnesyl transferase inhibitor, R115777 in the lung studies and budesonide, ketoprofen and sulindac in the bladder study...
  12. BIOADHESIVE MICROSPHERES FOR COLON CANCER THERAPY
    NEJAT EGILMEZ; Fiscal Year: 2002
    ..Following their loading with either sulindac (a nonsteroidal anti-inflammatory drug with antitumor activity) and/or Interleukin-12 (a potent immunostimulatory ..
  13. Colon Cancer Prevention with Phospho-Sulindac
    Basil Rigas; Fiscal Year: 2009
    A significant development in combination chemoprevention is the use of sulindac plus difluoromethylornithine (DFMO), which was recently demonstrated to reduce the recurrence of all human colon adenomas by 69% and of advanced adenomas by ..
  14. Colon Cancer Prevention with Phospho-Sulindac
    Basil Rigas; Fiscal Year: 2010
    A significant development in combination chemoprevention is the use of sulindac plus difluoromethylornithine (DFMO), which was recently demonstrated to reduce the recurrence of all human colon adenomas by 69% and of advanced adenomas by ..
  15. Characterization of a novel nuclear Rab protein
    Ying Huang; Fiscal Year: 2007
    ..expression is down-regulated by apoptosis inducing agents such as ultraviolet radiation (UV), thapsigargin and sulindac sulfide...
  16. Colonoscopic Analysis of Response of Murine Colon Lesions to Drug Intervention
    MARGIE CLAPPER; Fiscal Year: 2007
    ..the heterogeneous inhibitory response of colon adenomas to the nonsteroidal anti-inflammatory drug (NSAID) sulindac as seen in humans...
  17. Modulation of carcinogen-metabolizing enzyzmes by sulindac
    Henry Ciolino; Fiscal Year: 2007
    ..One promising colon chemopreventive agent is sulindac, a non-steroidal anti-inflammatory drug (NSAID) routinely prescribed to alleviate chronic pain and inflammation...
  18. Characterization of a novel ER membrane protein SPOC
    Ying Huang; Fiscal Year: 2005
    ..Thapsigargin and sulindac sulfide are known to perturb intracellular Ca2+ homeostasis by promoting ER Ca2+ pool depletion...
  19. Altered Arachidonic Acid Balance and Colon Cancer
    Daniel Rosenberg; Fiscal Year: 2007
    ..Aim 3 will test the influence of cPLA2 on chemoprevention by the Cox inhibitor, sulindac. Efficacy will be evaluated in mice with normal or reduced levels of cPLA2...
  20. Altered Arachidonic Acid Balance and Colon Cancer
    DANIEL WILLIAM ROSENBERG; Fiscal Year: 2010
    ..Aim 3 will test the influence of cPLA2 on chemoprevention by the Cox inhibitor, sulindac. Efficacy will be evaluated in mice with normal or reduced levels of cPLA2...
  21. Enhanced Killing of Cancer Cell by Sulindac and Oxidative Stress
    Herbert Weissbach; Fiscal Year: 2007
    b>Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenases (COX) 1 and 2. It is a prodrug which in the body is converted to the active COX inhibitor, sulindac sulfide...
  22. Altered Arachidonic Acid Balance and Colon Cancer
    Daniel Rosenberg; Fiscal Year: 2006
    ..Aim 3 will test the influence of cPLA2 on chemoprevention by the Cox inhibitor, sulindac. Efficacy will be evaluated in mice with normal or reduced levels of cPLA2...
  23. Planning a Trial of Sulindac for Oral Leukoplakia
    Jay Boyle; Fiscal Year: 2005
    Funding is requested to plan a multi-center, randomized, double-blind, placebo-controlled chemoprevention trial of sulindac for oral leukoplakia through an international collaboration between Memorial Sloan-Kettering Cancer Center (MSKCC) ..
  24. SMAC in chemoprevention of colon cancer
    Lin Zhang; Fiscal Year: 2010
    ..Furthermore, activation of SMAC and agents that mimic the function of SMAC can enhance the apoptotic response to sulindac, an NSAID commonly used in chemoprevention...
  25. SMAC in chemoprevention of colon cancer
    Lin Zhang; Fiscal Year: 2009
    ..Agents that mimic the function of SMAC can enhance the apoptotic response to sulindac, an NSAID commonly used in chemoprevention...
  26. SMAC in chemoprevention of colon cancer
    Lin Zhang; Fiscal Year: 2007
    ..Furthermore, activation of SMAC and agents that mimic the function of SMAC can enhance the apoptotic response to sulindac, an NSAID commonly used in chemoprevention...
  27. Chemopreventive Effect of NSAIDs Against Prostate Cancer
    Bhagavathi Narayanan; Fiscal Year: 2009
    ..It is not clear however, whether selective COX-2 inhibitors, or exisulind, a metabolic product of sulindac (NSAID), exert their potentially beneficial effects either by blocking COX-2 or by stimulating programmed cell ..
  28. ESOPHAGEAL ADENOCARCINOGENESIS AND ITS PREVENTION
    Chung Yang; Fiscal Year: 2001
    ..3) To investigate the possible inhibition of BE/EAC formation by nonsteroidal anti-inflammatory drugs (NSAIDs). Sulindac, sulindac sulfone, and selective cyclooxygenase 2 (COX-2) inhibitors will be used to examine the roles of ..